GEODE CAPITAL MANAGEMENT, LLC - TG THERAPEUTICS INC ownership

TG THERAPEUTICS INC's ticker is TGTX and the CUSIP is 88322Q108. A total of 101 filers reported holding TG THERAPEUTICS INC in Q1 2017. The put-call ratio across all filers is 0.64 and the average weighting 0.1%.

Quarter-by-quarter ownership
GEODE CAPITAL MANAGEMENT, LLC ownership history of TG THERAPEUTICS INC
ValueSharesWeighting
Q2 2024$57,052,520
+20.7%
3,206,390
+3.2%
0.01%
+25.0%
Q1 2024$47,270,980
-10.6%
3,107,444
+0.3%
0.00%
-33.3%
Q4 2023$52,896,881
+115.6%
3,096,646
+5.5%
0.01%
+100.0%
Q3 2023$24,529,870
-65.1%
2,933,826
+3.6%
0.00%
-62.5%
Q2 2023$70,311,854
+74.5%
2,830,589
+5.6%
0.01%
+60.0%
Q1 2023$40,304,207
+131634.6%
2,679,800
+3.6%
0.01%
+25.0%
Q4 2022$30,595
-99.8%
2,586,273
+7.3%
0.00%
+100.0%
Q3 2022$14,269,000
+44.5%
2,410,439
+3.7%
0.00%
+100.0%
Q2 2022$9,875,000
-52.6%
2,323,604
+6.2%
0.00%
-66.7%
Q1 2022$20,812,000
-52.6%
2,188,471
-5.3%
0.00%
-40.0%
Q4 2021$43,886,000
-42.7%
2,309,837
+0.3%
0.01%
-50.0%
Q3 2021$76,623,000
-8.4%
2,302,378
+6.8%
0.01%
-16.7%
Q2 2021$83,657,000
-15.2%
2,156,676
+5.3%
0.01%
-20.0%
Q1 2021$98,686,000
+6.7%
2,047,432
+15.1%
0.02%
-6.2%
Q4 2020$92,511,000
+112.9%
1,778,387
+9.5%
0.02%
+77.8%
Q3 2020$43,454,000
+48.7%
1,623,842
+8.2%
0.01%
+50.0%
Q2 2020$29,230,000
+121.6%
1,500,547
+11.9%
0.01%
+100.0%
Q1 2020$13,190,000
-46.0%
1,340,533
-39.1%
0.00%0.0%
Q4 2019$24,436,000
+290.2%
2,201,606
+97.4%
0.00%
+200.0%
Q3 2019$6,262,000
-30.0%
1,115,345
+7.8%
0.00%
-50.0%
Q2 2019$8,949,000
+19.9%
1,034,629
+11.5%
0.00%0.0%
Q1 2019$7,462,000
+20.5%
928,149
-38.5%
0.00%
+100.0%
Q4 2018$6,192,000
+61.5%
1,510,410
+120.6%
0.00%0.0%
Q3 2018$3,834,000
-50.5%
684,807
+16.3%
0.00%
-50.0%
Q2 2018$7,744,000
+9.5%
588,930
+18.2%
0.00%0.0%
Q1 2018$7,075,000
+86.7%
498,251
+7.8%
0.00%
+100.0%
Q4 2017$3,790,000
-29.5%
462,270
+1.9%
0.00%
-50.0%
Q3 2017$5,374,000
+24.1%
453,571
+5.3%
0.00%0.0%
Q2 2017$4,329,000
+2.6%
430,754
+18.9%
0.00%0.0%
Q1 2017$4,221,000
+211.5%
362,353
+24.3%
0.00%
+100.0%
Q4 2016$1,355,000
-37.9%
291,602
+3.4%
0.00%0.0%
Q3 2016$2,183,000
+29.9%
282,125
+1.7%
0.00%0.0%
Q2 2016$1,680,000
-28.8%
277,277
+0.1%
0.00%0.0%
Q1 2016$2,361,000
-21.3%
277,119
+10.1%
0.00%
-50.0%
Q4 2015$3,001,000
+20.3%
251,602
+1.6%
0.00%0.0%
Q3 2015$2,495,000
-38.5%
247,616
+1.2%
0.00%0.0%
Q2 2015$4,059,000
+35.4%
244,720
+26.3%
0.00%0.0%
Q1 2015$2,998,000
+3.0%
193,698
+5.3%
0.00%0.0%
Q4 2014$2,912,000
+54.8%
183,886
+4.3%
0.00%
+100.0%
Q3 2014$1,881,000
+14.8%
176,313
+1.0%
0.00%0.0%
Q2 2014$1,638,000
+56.1%
174,507
+14.7%
0.00%0.0%
Q1 2014$1,049,000
+206.7%
152,167
+73.5%
0.00%
Q4 2013$342,000
-22.4%
87,707
+1.3%
0.00%
Q3 2013$441,000
+267.5%
86,604
+360.9%
0.00%
Q2 2013$120,00018,7900.00%
Other shareholders
TG THERAPEUTICS INC shareholders Q1 2017
NameSharesValueWeighting ↓
Opaleye Management Inc. 2,280,000$40,561,2009.27%
Soleus Capital Management, L.P. 3,645,562$64,854,5485.72%
Exome Asset Management LLC 251,600$4,475,9643.90%
M28 Capital Management LP 161,600$2,874,8643.73%
Ghost Tree Capital, LLC 500,000$8,895,0002.78%
683 Capital Management, LLC 1,400,000$24,906,0001.88%
Sofinnova Investments, Inc. 1,861,277$33,112,1181.72%
Deep Track Capital, LP 2,870,131$51,059,6301.52%
Parkwood LLC 147,680$9,8471.22%
Spotlight Asset Group, Inc. 82,100$1,460,5591.02%
View complete list of TG THERAPEUTICS INC shareholders